Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of Bilayer Tablet Containing Saxagliptin Immediate Release and Metformin Sustained Release Using Quality by Design Approach

Author(s): Amit Kaushal, Sandeep Arora, Neelam Sharma and Sukhbir Singh*

Volume 16, Issue 2, 2021

Published on: 15 March, 2021

Page: [184 - 203] Pages: 20

DOI: 10.2174/1574885516666210315100848

Price: $65

Abstract

Objective: Adequate glycemic control in diabetes patients requires oral combination therapy. Saxagliptin is a dipeptidyl peptidase-4 inhibitor having fewer adverse effects, and metformin is the first-line medicine for diabetes treatment. The aim of this research work is to develop a bilayer tablet of saxagliptin and metformin in fixed-dose combination (FDC) using quality by design (QbD) to acquire the immediate release of saxagliptin and sustained release of metformin from bilayer tablet to ultimately achieve superior patient compliance.

Methods: The development of the bilayer tablet was done in four stages using QbD. In the first step, quality target product profile (QTPP) of bilayer tablet was defined, and critical quality attributes (CQAs) were identified by risk estimation matrix and taguchi design; an immediate release saxagliptin layer was optimized in the second step, optimization of sustained-release metformin layer was carried out in the third step, and in the final step, bilayer tablet was prepared and characterized. The effect of independent parameters, i.e., magnesium stearate level (X1), kneading time (X2) and lubrication time (X3) on Carr’s Index (Y1), percentage relative standard deviation of content uniformity (Y2) and drug release at 30 minutes (Y3), were estimated for optimization of immediate release saxagliptin layer using Box-Behnken design (BBD). The effect of independent parameters, i.e., hydroxypropyl methylcellulose level (X4), compritol level (X5) and magnesium stearate level (X6) on Carr’s Index (Y4), drug release at 2 h (Y5), drug release at 5 h (Y6) and drug release at 10 h (Y7) were estimated for optimization of sustained-release metformin layer using BBD.

Results: The optimized composition of immediate release saxagliptin layer estimated using numerical optimization by Design expert was 0.88% (X1), 15 minutes (X2) and 3.85 minutes (X3) with predicted variables, i.e., 10.59% (Y1), 3.16% (Y2) and 85% (Y3). The optimized composition of sustained- release saxagliptin layer predicted through numerical optimization was 30% (X4), 3.36% (X5) and 0.9% (X6) having 10.89% (Y4), 43.44% (Y5), 60% (Y6) and 85.14% (Y7). In-vitro dissolution study of bilayer tablet showed immediate release of Saxagliptin (approximately 85% in 30 minutes) and sustained release of metformin illustrating 43.21±1.21, 60.86±2.96 and 86.26±1.38% drug release at 2, 5 and 10 h, respectively. The release exponent for the Korsmeyer-Peppas model for Saxagliptin and metformin was 0.237 (<0.45) and 1.536 (n>0.85), indicating Fickian and super case II transport drug release behavior, respectively.

Conclusion: By QbD approach, bilayer tablet containing saxagliptin and metformin was successfully developed, and influence of various formulation parameters on CQAs of drug products was understood with fewer experiments. This leads to the conclusion that cost can be reduced using QbD in the development of FDC for improving patient compliance.

Keywords: Bilayer, box-behnken design, critical quality attributes, quality by design, quality target product profile, saxagliptin, taguchi design.

« Previous Next »
Graphical Abstract

[1]
Tandon N, Anjana RM, Mohan V, et al. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health 2018; 6(12): e1352-62.
[http://dx.doi.org/10.1016/S2214-109X(18)30387-5] [PMID: 30219315]
[2]
García-Pérez LE, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013; 4(2): 175-94.
[http://dx.doi.org/10.1007/s13300-013-0034-y] [PMID: 23990497]
[3]
Saeedi P, Salpea P, Karuranga S, et al. Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: Results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract 2020; 162: 108086.
[4]
Harris SB. The power of two: an update on fixed-dose combinations for type 2 diabetes. Expert Rev Clin Pharmacol 2016; 9(11): 1453-62.
[http://dx.doi.org/10.1080/17512433.2016.1221758] [PMID: 27498671]
[5]
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018; 14(2): 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID: 29219149]
[6]
Meneghini L, Hirsch IB. Pharmacotherapies for diabetes management: an update for the practicing clinician. Semin Thorac Cardiovasc Surg 2006; 18(4): 379-89.
[http://dx.doi.org/10.1053/j.semtcvs.2007.01.003] [PMID: 17395035]
[7]
Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009; 122(5): 443-53.
[http://dx.doi.org/10.1016/j.amjmed.2008.09.047] [PMID: 19375554]
[8]
Hayes J, Anderson R, Stephens JW. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Drug Des Devel Ther 2016; 10: 2263-70.
[http://dx.doi.org/10.2147/DDDT.S93076] [PMID: 27486305]
[9]
Mudaliar S, Henry RR, Robert R. Combination therapy for type 2 diabetes. Endocr Pract 1999; 5(4): 208-19.
[http://dx.doi.org/10.4158/EP.5.4.208] [PMID: 15251678]
[10]
Charpentier G. Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 2002; 18(S3): S70-6.
[http://dx.doi.org/10.1002/dmrr.278] [PMID: 12324989]
[11]
Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10(5): 376-86.
[http://dx.doi.org/10.1111/j.1463-1326.2008.00876.x] [PMID: 18355324]
[12]
Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011; 34(2)(Suppl. 2): S276-8.
[http://dx.doi.org/10.2337/dc11-s229] [PMID: 21525468]
[13]
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-26.
[http://dx.doi.org/10.1056/NEJMoa1307684] [PMID: 23992601]
[14]
Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65(12): 1230-9.
[http://dx.doi.org/10.1111/j.1742-1241.2011.02812.x] [PMID: 21977965]
[15]
Song R. Mechanism of metformin: a tale of two sites. Diabetes Care 2016; 39(2): 187-9.
[http://dx.doi.org/10.2337/dci15-0013] [PMID: 26798149]
[16]
DeFronzo R, Hissa MN, Garber A, et al. Once-daily saxagliptin added to metformin provides sustained glycaemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. 2009.
[17]
Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011; 27(4): 863-9.
[http://dx.doi.org/10.1185/03007995.2011.554532] [PMID: 21323504]
[18]
Desai D, Wang J, Wen H, Li X, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol 2013; 18(6): 1265-76.
[http://dx.doi.org/10.3109/10837450.2012.660699] [PMID: 22339230]
[19]
Lavernia F, Adkins SE, Shubrook JH. Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals. Postgrad Med 2015; 127(8): 808-17.
[http://dx.doi.org/10.1080/00325481.2015.1085293] [PMID: 26439384]
[20]
Kannan S, Mahadevan S, Ramakrishnan A. Fixed dose combinations for type 2 diabetes. Lancet Diabetes Endocrinol 2015; 3(6): 408.
[http://dx.doi.org/10.1016/S2213-8587(15)00137-0] [PMID: 26003756]
[21]
Kaplan W, Laing R. Fixed dose combinations as an innovative delivery mechanism. Priority mechanisms for europe and the world a public health approach to innovation 2004.
[22]
Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab 2013; 15(4): 291-300.
[http://dx.doi.org/10.1111/dom.12015] [PMID: 23013323]
[23]
Nirmal J, Saisivam S, Peddanna C, Muralidharan S, Godwinkumar S, Nagarajan M. Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation. Chem Pharm Bull (Tokyo) 2008; 56(10): 1455-8.
[http://dx.doi.org/10.1248/cpb.56.1455] [PMID: 18827389]
[24]
Shiyani B, Gattani S, Surana S. Formulation and evaluation of bi-layer tablet of metoclopramide hydrochloride and ibuprofen. AAPS PharmSciTech 2008; 9(3): 818-27.
[http://dx.doi.org/10.1208/s12249-008-9116-y] [PMID: 18612830]
[25]
Vervaeck A, Monteyne T, Saerens L, De Beer T, Remon JP, Vervaet C. Prilling as manufacturing technique for multiparticulate lipid/PEG fixed-dose combinations. Eur J Pharm Biopharm 2014; 88(2): 472-82.
[http://dx.doi.org/10.1016/j.ejpb.2014.06.018] [PMID: 25010389]
[26]
Vynckier AK, Dierickx L, Saerens L, et al. Hot-melt co-extrusion for the production of fixed-dose combination products with a controlled release ethylcellulose matrix core. Int J Pharm 2014; 464(1-2): 65-74.
[http://dx.doi.org/10.1016/j.ijpharm.2014.01.028] [PMID: 24486558]
[27]
Charlton S, Nicholson S. A novel immediate release active film coat formulation for use with an extended release gel matrix tablet core. J Pharm Pharmacol 2010; 62(10): 1397-8.
[28]
Mohammed GA, Puri V, Bansal AK. Coprocessing of nevirapine and stavudine by spray drying. Pharm Dev Technol 2008; 13(4): 299-310.
[http://dx.doi.org/10.1080/10837450802089164] [PMID: 18649220]
[29]
Pramod K, Tahir MA, Charoo NA, Ansari SH, Ali J. Pharmaceutical product development: A quality by design approach. Int J Pharm Investig 2016; 6(3): 129-38.
[http://dx.doi.org/10.4103/2230-973X.187350] [PMID: 27606256]
[30]
Jannat E, Arif A, Hasan MM, et al. Granulation Techniques & Its Updated Modules. Pharma Innov J 2016; 05: 134-41.
[31]
Oliveira PR, Mendes C, Klein L, Sangoi MdaS, Bernardi LS, Silva MA. Formulation development and stability studies of norfloxacin extended-release matrix tablets. BioMed Res Int 2013; 2013: 716736.
[http://dx.doi.org/10.1155/2013/716736] [PMID: 24083235]
[32]
Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012; 38(2): 89-101.
[http://dx.doi.org/10.1016/j.diabet.2011.11.001] [PMID: 22197148]
[33]
Bansal S, Beg S, Asthana A, et al. QbD-enabled systematic development of gastroretentive multiple-unit microballoons of itopride hydrochloride. Drug Deliv 2016; 23: 437-51.
[http://dx.doi.org/10.3109/10717544.2014.916771] [PMID: 24865292]
[34]
Jose S, Fangueiro JF, Smitha J, et al. Cross-linked chitosan microspheres for oral delivery of insulin: Taguchi design and in vivo testing. Colloids Surf B Biointerfaces 2012; 92: 175-9.
[http://dx.doi.org/10.1016/j.colsurfb.2011.11.040] [PMID: 22221459]
[35]
Krupa AND, Abigail MEA, Santhosh C, et al. Optimization of process parameters for the microbial synthesis of silver nanoparticles using 3-level Box-Behnken Design. Ecol Eng 2016; 87: 168-74.
[http://dx.doi.org/10.1016/j.ecoleng.2015.11.030]
[36]
Singh B, Garg B, Bhatowa R, et al. Systematic development of a gastroretentive fixed dose combination of lamivudine and zidovudine for increased patient compliance. J Drug Deliv Sci Technol 2017; 37: 204-15.
[http://dx.doi.org/10.1016/j.jddst.2016.12.014]
[37]
Garg NK, Sharma G, Singh B, et al. Quality by design (QbD)-based development and optimization of a simple, robust RP-HPLC method for the estimation of methotrexate. J Liq Chrom Rel Technol 2015; 38(17): 1629-37.
[http://dx.doi.org/10.1080/10826076.2015.1087409]
[38]
Koteswari P, Puttugunta SB, Vadlatala G. Formulation development and evaluation of bi layer tablets: a fixed dose combination of sumatriptan succinate and naproxen sodium as immediate release layer and sumatriptan succinate as delayed release layer. J Pharm Investig 2014; 44(3): 187-96.
[http://dx.doi.org/10.1007/s40005-013-0114-z]
[39]
Dey S, Chattopadhyay S, Mazumder B. Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release. BioMed Res Int 2014; 2014: 396106.
[http://dx.doi.org/10.1155/2014/396106] [PMID: 24527446]
[40]
Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS PharmSciTech 2003; 4(3): E31.
[http://dx.doi.org/10.1208/pt040331] [PMID: 14621963]
[41]
Yang C, Li W. Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension. patent US 9115082 B2, 2015.
[42]
Peppas NA, Sahlin JJ. A simple equation for the description of solute release. iii. coupling of diffusion and relaxation. Int J Pharm 1989; 57: 169-72.
[http://dx.doi.org/10.1016/0378-5173(89)90306-2]
[43]
Piscitelli DA, Young D. Setting dissolution specifications for modified-release dosage forms.In Vitro-in Vivo Correlations Springer, US. Springer, US 1997; pp. pp. 159-166.
[http://dx.doi.org/10.1007/978-1-4684-6036-0_13]
[44]
Bruschi ML. Strategies to modify the drug release from pharmaceutical systems. (1st ed.). United Kingdom: Woodhead Publishing. United Kingdom: Woodhead Publishing 2015; pp. pp. 63-86.
[45]
Namjoshi S, Dabbaghi M, Roberts MS, Grice JE, Mohammed Y. Quality by design: Development of the quality target product profile (QTPP) for semisolid topical products. Pharmaceutics 2020; 12(3): 287.
[http://dx.doi.org/10.3390/pharmaceutics12030287] [PMID: 32210126]
[46]
Swain S, Parhi R, Jena BR, Babu SM. Quality by design: concept to applications. Curr Drug Discov Technol 2019; 16(3): 240-50.
[http://dx.doi.org/10.2174/1570163815666180308142016] [PMID: 29521238]
[47]
Xu X, Khan MA, Burgess DJ. A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. Int J Pharm 2011; 419(1-2): 52-9.
[http://dx.doi.org/10.1016/j.ijpharm.2011.07.012] [PMID: 21787854]
[48]
Lee AR, Kwon SY, Choi DH, Park ES. Quality by Design (QbD) approach to optimize the formulation of a bilayer combination tablet (Telmiduo®) manufactured via high shear wet granulation. Int J Pharm 2017; 534(1-2): 144-58.
[http://dx.doi.org/10.1016/j.ijpharm.2017.10.004] [PMID: 29031980]
[49]
Morin G, Briens L. The effect of lubricants on powder flowability for pharmaceutical application. AAPS PharmSciTech 2013; 14(3): 1158-68.
[http://dx.doi.org/10.1208/s12249-013-0007-5] [PMID: 23897035]
[50]
Li W, Bashai-Woldu A, Ballard J, et al. Applications of NIR in early stage formulation development. Part I. Semi-quantitative blend uniformity and content uniformity analyses by reflectance NIR without calibration models. Int J Pharm 2007; 340(1-2): 97-103.
[http://dx.doi.org/10.1016/j.ijpharm.2007.03.040] [PMID: 17467204]
[51]
Mahours GM, Shaaban DEZ, Shazly GA, et al. The effect of binder concentration and dry mixing time on granules, tablet characteristics and content uniformity of low dose drug in high shear wet granulation. J Drug Deliv Sci Technol 2017; 39: 192-9.
[http://dx.doi.org/10.1016/j.jddst.2017.03.014]
[52]
Han JK, Shin BS, Choi DH. Comprehensive study of intermediate and critical quality attributes for process control of high-shear wet granulation using multivariate analysis and the quality by design approach. Pharmaceutics 2019; 11(6): 252.
[http://dx.doi.org/10.3390/pharmaceutics11060252] [PMID: 31159393]
[53]
Pilpel N, Otuyemi SO, Kurup TR. Factors affecting the disintegration and dissolution of chloroquine phosphate/starch tablets. J Pharm Pharmacol 1978; 30(4): 214-9.
[http://dx.doi.org/10.1111/j.2042-7158.1978.tb13207.x] [PMID: 24707]
[54]
Grzegorzewski P. Statistical tests for comparing pareto charts. Commun Numer Analysis 2012; 2012: 1-12.
[http://dx.doi.org/10.5899/2012/cna-00110]
[55]
Hu X, Wang H, Liu Y. Statistical analysis of main and interaction effects on Cu(II) and Cr(VI) decontamination by nitrogen-doped magnetic graphene oxide. Sci Rep 2016; 6(1): 34378.
[http://dx.doi.org/10.1038/srep34378] [PMID: 27694891]
[56]
Liang J, Cheng L, Struckhoff JJ, Ravi N. Investigating triazine-based modification of hyaluronan using statistical designs. Carbohydr Polym 2015; 132: 472-80.
[http://dx.doi.org/10.1016/j.carbpol.2015.06.067] [PMID: 26256372]
[57]
Ghorab MK, Adeyeye MC. High shear mixing granulation of ibuprofen and β-cyclodextrin: effects of process variables on ibuprofen dissolution. AAPS PharmSciTech 2007; 8(4): E84.
[http://dx.doi.org/10.1208/pt0804084] [PMID: 18181545]
[58]
Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013; 434(2): 191-6.
[http://dx.doi.org/10.1016/j.bbrc.2013.03.010] [PMID: 23501107]
[59]
Nakamura S, Tanaka C, Yuasa H, Sakamoto T. Utility of microcrystalline cellulose for improving drug content uniformity in tablet manufacturing using direct powder compression. AAPS PharmSciTech 2019; 20(4): 151.
[http://dx.doi.org/10.1208/s12249-019-1365-4] [PMID: 30903317]
[60]
Kuncahyo I, Choiri S. The influence of magnesium stearate, purified talc and combination of both on ternary/quaternary interactive mixture of freely and poorly water-soluble drug. Int J Pharm Pharm Sci 2014; 7(1): 397-402.
[61]
Uzunović A, Vranić E. Effect of magnesium stearate concentration on dissolution properties of ranitidine hydrochloride coated tablets. Bosn J Basic Med Sci 2007; 7(3): 279-83.
[http://dx.doi.org/10.17305/bjbms.2007.3060] [PMID: 17848158]
[62]
Kharia AA, Singhai AK. Screening of most effective variables for development of gastroretentive mucoadhesive nanoparticles by taguchi design. ISRN Nanomater 2013; 2013: 348095.
[http://dx.doi.org/10.1155/2013/348095]
[63]
Barakat NS, Elbagory IM, Almurshedi AS. Controlled-release carbamazepine granules and tablets comprising lipophilic and hydrophilic matrix components. AAPS PharmSciTech 2008; 9(4): 1054-62.
[http://dx.doi.org/10.1208/s12249-008-9140-y] [PMID: 18843537]
[64]
Parikh K, Mundada P, Sawant K. Design and optimization of controlled release felbamate tablets by d-optimal mixture design: in vitro-in vivo evaluation. Indian J Pharm Sci 2019; 81(1): 71-81.
[http://dx.doi.org/10.4172/pharmaceutical-sciences.1000481]
[65]
Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 2001; 48(2-3): 139-57.
[http://dx.doi.org/10.1016/S0169-409X(01)00112-0] [PMID: 11369079]
[66]
Siepmann J, Siepmann F. Modeling of diffusion controlled drug delivery. J Control Release 2012; 161(2): 351-62.
[http://dx.doi.org/10.1016/j.jconrel.2011.10.006] [PMID: 22019555]
[67]
Ghosal K, Chandra A, Rajabalaya R, Chakraborty S, Nanda A. Mathematical modeling of drug release profiles for modified hydrophobic HPMC based gels. Pharmazie 2012; 67(2): 147-55.
[PMID: 22512085]
[68]
Ahuja N, Katare OP, Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur J Pharm Biopharm 2007; 65(1): 26-38.
[http://dx.doi.org/10.1016/j.ejpb.2006.07.007] [PMID: 16962750]
[69]
Momin MM, Kane S, Abhang P. Formulation and evaluation of bilayer tablet for bimodal release of venlafaxine hydrochloride. Front Pharmacol 2015; 6: 144.
[http://dx.doi.org/10.3389/fphar.2015.00144] [PMID: 26217229]
[70]
Ryakala H, Dineshmohan S, Ramesh A, Gupta VR. Formulation and in vitro evaluation of bilayer tablets of nebivolol hydrochloride and nateglinide for the treatment of diabetes and hypertension. J Drug Deliv 2015; 2015: 827859.
[http://dx.doi.org/10.1155/2015/827859] [PMID: 25648606]
[71]
Singh B, Saini G, Vyas M, et al. Optimized chronomodulated dual release bilayer tablets of fexofenadine and montelukast: quality by design, development, and in vitro evaluation. Futur J Pharm Sci 2019; 5: 5.
[http://dx.doi.org/10.1186/s43094-019-0006-9]
[72]
Mehrgan H, Mortazavi SA. The release behavior and kinetic evaluation of atenolol from various hydrophilic and plastic based matrices. Iran J Pharm Res 2005; 3: 137-46.
[73]
Conti S, Maggi L, Segale L, et al. Matrices containing NaCMC and HPMC 1. Dissolution performance characterization. Int J Pharm 2007; 333(1-2): 136-42.
[http://dx.doi.org/10.1016/j.ijpharm.2006.11.059] [PMID: 17207943]
[74]
Talukdar MM, Kinget R. Comparative study on xanthan gum and hydroxypropylmethyl cellulose for controlled-release drug delivery. II. Drug diffusion in hydrated matrices. Int J Pharm 1997; 151: 99-107.
[http://dx.doi.org/10.1016/S0378-5173(97)04896-5]
[75]
Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 13(2): 123-33.
[http://dx.doi.org/10.1016/S0928-0987(01)00095-1] [PMID: 11297896]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy